Nicolas Wernert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nicolas Wernert has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
A. Wellmann
Institute of Pathology, University of Bonn, Sigmund-Freud-Straße 25, D-53105 Bonn, Germany
1 shared publicationAnja Hügel
Institut für Pathologie der Universität, Postfach 2120, D‐53011 Bonn, Germany, Fax: (+49) 228‐287‐50‐30
1 shared publicationAntje Stanjek
Institut für Organische Chemie der Universität, Richard‐Willstätter‐Allee 2, D‐76128 Karlsruhe, Germany, Fax: (+49) 721‐608‐7652
1 shared publication- Athanassios Giannis
Institut für Organische Chemie der Universität, Richard‐Willstätter‐Allee 2, D‐76128 Karlsruhe, Germany, Fax: (+49) 721‐608‐7652
1 shared publication Hem Chandra Jha
Institut für Physiologische Chemie der Universität Bonn, Germany
1 shared publicationJ. Krischler
Institute of Pathology, University of Bonn, Sigmund-Freud-Straße 25, D-53105 Bonn, Germany
1 shared publication
Latest Publications
- 21 March 2001
- Published by Wiley in The Journal of Pathology
- Vol. 194 (1) , 43-50
The Ets-1 transcription factor is up-regulated together with MMP 1 and MMP 9 in the stroma of pre-invasive breast cancer
The first steps of stroma generation are of pivotal importance for carcinogenesis because at this stage are initiated both angiogenesis, the prerequisite for continuous tumour growth, and the proliferation of stromal fibroblasts. These developments contribute to the onset of tumour invasion by secreting several matrix-degrading proteases. Both angiogenesis and the production of proteases are tightly controlled at several levels; of significant importance is transcription. The Ets-1 transcription factor transactivates several genes encoding matrix-degrading proteases and is thought to be involved in both tumour vascularization and invasion. This study therefore investigated, by in situ hybridization and immunohistochemistry, the expression of Ets-1 and of two of its target genes, encoding matrix metalloproteinase (MMP) 1 and MMP 9, in order to demonstrate a topographical in vivo correlation between the expression of these three genes during breast cancer formation. All three genes were first expressed within both endothelial cells and stromal fibroblasts during the onset of stroma generation around intraductal and intralobular in situ carcinomas and they were significantly up-regulated in the stroma of invasive ductal and lobular cancers. The results of this study further support the suggested in vivo role of Ets-1 for both angiogenesis and tumour invasion, via matrix-degrading proteases which are already expressed during the early stages of breast carcinogenesis. Copyright © 2001 John Wiley & Sons, Ltd.
- 21 March 2001
- Published by Wiley in The Journal of Pathology
- Vol. 194 (1) , 43-50
The Ets-1 transcription factor is up-regulated together with MMP 1 and MMP 9 in the stroma of pre-invasive breast cancer
The first steps of stroma generation are of pivotal importance for carcinogenesis because at this stage are initiated both angiogenesis, the prerequisite for continuous tumour growth, and the proliferation of stromal fibroblasts. These developments contribute to the onset of tumour invasion by secreting several matrix-degrading proteases. Both angiogenesis and the production of proteases are tightly controlled at several levels; of significant importance is transcription. The Ets-1 transcription factor transactivates several genes encoding matrix-degrading proteases and is thought to be involved in both tumour vascularization and invasion. This study therefore investigated, by in situ hybridization and immunohistochemistry, the expression of Ets-1 and of two of its target genes, encoding matrix metalloproteinase (MMP) 1 and MMP 9, in order to demonstrate a topographical in vivo correlation between the expression of these three genes during breast cancer formation. All three genes were first expressed within both endothelial cells and stromal fibroblasts during the onset of stroma generation around intraductal and intralobular in situ carcinomas and they were significantly up-regulated in the stroma of invasive ductal and lobular cancers. The results of this study further support the suggested in vivo role of Ets-1 for both angiogenesis and tumour invasion, via matrix-degrading proteases which are already expressed during the early stages of breast carcinogenesis. Copyright © 2001 John Wiley & Sons, Ltd.
- 2 November 1999
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 38 (21) , 3228-3231
Inhibition of Angiogenesis In Vivo byets-1 Antisense Oligonucleotides—Inhibition of Ets-1 Transcription Factor Expression by the Antibiotic Fumagillin
The inhibition of angiogenesis in vivo as a result of the inhibition of Ets-1 transcription factor expression by the ets-1 phosphorothioate antisense oligodeoxynucleotide 5′-AGATCGACGGCCGCCTTCAT-3′ has been proven by experiments with chicken embryos. Thus, participation of the Ets-1 transcription factor in the formation of new blood vessels in vivo has been demonstrated. Furthermore, it is shown that the angiostatic effect of the fungal metabolite and angiogenesis inhibitor fumagillin is mainly a result of its ability to inhibit Ets-1 expression.
- 2 November 1999
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 38 (21) , 3228-3231
Inhibition of Angiogenesis In Vivo byets-1 Antisense Oligonucleotides—Inhibition of Ets-1 Transcription Factor Expression by the Antibiotic Fumagillin
The inhibition of angiogenesis in vivo as a result of the inhibition of Ets-1 transcription factor expression by the ets-1 phosphorothioate antisense oligodeoxynucleotide 5′-AGATCGACGGCCGCCTTCAT-3′ has been proven by experiments with chicken embryos. Thus, participation of the Ets-1 transcription factor in the formation of new blood vessels in vivo has been demonstrated. Furthermore, it is shown that the angiostatic effect of the fungal metabolite and angiogenesis inhibitor fumagillin is mainly a result of its ability to inhibit Ets-1 expression.